Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16279551 | 1.00 | MEN1 (0.34) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL31108444 | 0.89 | KMT2A (0.41) | MEN1KMT2ASMN1; SMN2RAB9ACYP3A4 | |
| SCHEMBL17798538 | 0.88 | FAP (0.40) | MEN1KMT2AHRH1ALDH1A1L3MBTL1 | |
| SCHEMBL17798539 | 0.88 | FAP (0.40) | MEN1KMT2AHRH1ALDH1A1L3MBTL1 | |
| SCHEMBL17798537 | 0.88 | FAP (0.40) | MEN1KMT2AHRH1ALDH1A1L3MBTL1 | |
| SCHEMBL32667900 | 0.81 | FAP (0.36) | MEN1KMT2AHRH1ALDH1A1L3MBTL1 | |
| SCHEMBL16279554 | 0.81 | HTR2A (0.45) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL16410939 | 0.81 | HTR2A (0.45) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL16285134 | 0.81 | HTR2A (0.45) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL28957936 | 0.78 | FAP (0.40) | HRH1POLBMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20180147294-A1 | ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | SDCBP, CD81, DSTN | MEN1 597/4885KMT2A 1990/4885SMN1; SMN2 3426/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | MEN1 2794/4885KMT2A 2470/4885SMN1; SMN2 3212/4885 |
| US-20180147294-A1 | ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE | SDCBP, CD81, DSTN | MEN1 597/4885KMT2A 1990/4885SMN1; SMN2 3426/4885 |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MEN1 3881/4885KMT2A 1606/4885SMN1; SMN2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.